A Phase 2 Study of HSK47388 Tablets to Evaluate the Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis
PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
220
Participants
Timeline
Start Date
September 1, 2025
Primary Completion Date
December 20, 2026
Study Completion Date
January 17, 2027
Conditions
Plaque Psoriasis
Interventions
DRUG
HSK47388
HSK47388 tablets will be administered orally, once a day
All Listed Sponsors
lead
Haisco Pharmaceutical Group Co., Ltd.
INDUSTRY
NCT07158268 - A Phase 2 Study of HSK47388 Tablets to Evaluate the Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter